A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.

Pfizer is “evaluating appropriate next steps” for its Duchenne muscular dystrophy (DMD) gene therapy after it failed a phase 3 trial. Fordadistrogene movaparvovec (PF-06939926) was unable to ...

The young boy was suffering from Duchenne muscular dystrophy (DMD), a ... that the patient received the gene therapy in early 2023, as per a report from Pfizer. "We do not yet have complete ...

Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market.

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

For example, Duchenne muscular dystrophy presents early ... and productive communication between regulators and gene therapy researchers. Pfizer is leveraging its global regulatory expertise ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

(VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene autotemcel), an autologous genome edited hematopoietic stem cell-based therapy, for the treatment of ...